The capability to develop new anti-cancer agents is essential to the mission of the Cancer Center. The Translational Pharmacology and Early Therapeutic Trials (TPETT) Program accomplishes this by: 1) supporting the preclinical development of anti-cancer agents identified by DF/HCC investigators, and 2) defining the toxicity, pharmacokinetics and pharmacodynamics of new agents from the Center, NCI and pharmaceutical companies In Early Phase trials. The overall objective of the TPETT Program is, thus, to foster a coordinated effort: through which promising new leads and agents are developed for evaluation in Early Phase clinical trials and then in Phase 11 in conjunction with the Clinical-based Programs. The Program facilitates the development of anti-cancer agents by combining basic science and clinical resources at the DFCI, MGH, BWH, BIDMC and CHB.
Its Specific Aims are to: 1) strengthen and expand preclinical drug discovery and development efforts;2) perform translational studies to identify responsive subsets of tumors and confirm mechanism of action in the clinic;3) conduct Phase I, l-ll pharmacokinetic/pharmacodynamic trials of new anti-cancer agents with correlative laboratory and imaging studies to define biological endpoints and mechanisms;and 4) develop biomarkers for drug response, resistance and toxicity. The 49 members of this program represent six DF/HCC institutions and eight departments of HMS. In 2009, members received $10.4 million (total costs) in cancer-relevant funding, including $2.7 million from NCI and $370,000 from other peer-reviewed sponsors. In addition, members published 500 papers during the project period (2006 to 2010), of which 12.4% were intra-programmatic, 50% were inter-programmatic, and 25.4% were inter-institutional. The Program has been continuously funded as a CCSG Program for ten years. At the time of the last competitive renewal in 2005, the Program received Excellent merit.
|Lin, Ruei-Zeng; Lee, Chin Nien; Moreno-Luna, Rafael et al. (2017) Host non-inflammatory neutrophils mediate the engraftment of bioengineered vascular networks. Nat Biomed Eng 1:|
|Wang, Meng; Han, Jing; Marcar, Lynnette et al. (2017) Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res 77:2018-2028|
|Ignatius, Myron S; Hayes, Madeline N; Lobbardi, Riadh et al. (2017) The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Rep 19:2304-2318|
|Nugent, Alicia A; Park, Jong G; Wei, Yan et al. (2017) Mutant ?2-chimaerin signals via bidirectional ephrin pathways in Duane retraction syndrome. J Clin Invest 127:1664-1682|
|Breitkopf, Susanne B; Taveira, Mateus De Oliveira; Yuan, Min et al. (2017) Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland. Sci Rep 7:14503|
|Bowden, John A; Heckert, Alan; Ulmer, Candice Z et al. (2017) Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human Plasma. J Lipid Res 58:2275-2288|
|Lindsley, R Coleman; Saber, Wael; Mar, Brenton G et al. (2017) Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med 376:536-547|
|Mita, Monica M; Mita, Alain C; Moseley, Jennifer L et al. (2017) Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. Br J Cancer 117:1258-1268|
|Hu, Yuebi; Alden, Ryan S; Odegaard, Justin I et al. (2017) Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin Cancer Res 23:7351-7359|
|Lam, Hilaire C; Liu, Heng-Jia; Baglini, Christian V et al. (2017) Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. Oncotarget 8:64714-64727|
Showing the most recent 10 out of 371 publications